BioMark is proud to partner and cooperate with National Cancer Institute in Bangladesh and BioMark China in a phase III multi site trial. The trail will involve over 400 subjects and will focus on 4 cancer indications. All the procedures will follow North American regulatory guidelines that were prepared by Saint Boniface Research centre’s regulatory group.
News
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection
January 18, 2026
